Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Nivolumab
Related studies linked through entity extraction aliases.
Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)
- Status
- RECRUITING
- Phase
- PHASE2
An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer
- Status
- COMPLETED
- Phase
- PHASE2
ANIMATE: Phase II Study of Nivolumab Monotherapy for Relapsed/Refractory Hodgkin Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer
- Status
- COMPLETED
- Phase
- PHASE2
An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment
- Status
- COMPLETED
- Phase
- PHASE1
Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE2
Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma
- Status
- COMPLETED
- Phase
- PHASE3
Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting PD-1
- Status
- UNKNOWN
- Phase
- PHASE4
A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL
- Status
- COMPLETED
- Phase
- PHASE1
Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy
- Status
- TERMINATED
- Phase
- PHASE2